Health and Healthcare

Potential Deathblow for Chelsea (CHTP)

Chelsea Therapeutics International Ltd. (NASDAQ: CHTP) is being beaten hard this morning.  News hit that the FDA has now rejected the company’s Northera drug to treat low blood pressure for now in a complete response.  Effectively the FDA is asking Chelsea to provide more efficacy data.

Sadly, this could actually create a one or two year delay and the company was worth only $246 million before the news impact.  Chelsea has said that it still needs to have discussions with the FDA so that it can satisfy the FDA’s request.

The company believes that an ongoing trial might meet the FDA’s criteria but it is not sure if the FDA will require changes to the primary endpoint of Northera.  Unfortunately this is still just unfinished business.

Investors are shooting first and asking questions later.  Shares are down 28% at $2.62 in pre-market trading and the 52-week trading range is $2.18 to $6.06.  The NASDAQ pre-market trading alert has already gone over 800,000 shares and it is worth noting that the most recent short interest was at a yearly high of 7.26 million shares as of the March 15 settlement date.

The company is pre-revenue and it had about $45 million in liquidity at the end of the 2011 year.


ALERT: Take This Retirement Quiz Now  (Sponsored)

Take the quiz below to get matched with a financial advisor today.

Each advisor has been vetted by SmartAsset and is held to a fiduciary standard to act in your best interests.

Here’s how it works:
1. Answer SmartAsset advisor match quiz
2. Review your pre-screened matches at your leisure. Check out the advisors’ profiles.
3. Speak with advisors at no cost to you. Have an introductory call on the phone or introduction in person and choose whom to work with in the future

Take the retirement quiz right here.

Thank you for reading! Have some feedback for us?
Contact the 24/7 Wall St. editorial team.